About midostaurin
Kinase inhibitor
Used for
- Used with chemotherapy for newly diagnosed FLT3-mutated acute myeloid leukemia.
- Used for advanced systemic mastocytosis, including aggressive forms and mast cell leukemia.
Usual adult dose
AML: 50 mg twice daily on days 8–21 of each chemotherapy cycle. Mastocytosis: 100 mg twice daily continuously.
Common side effects
- Nausea, vomiting, and diarrhea
- Low blood cell counts and infections
- Swelling, headache, or muscle and bone pain
- Lung inflammation
Important warnings
- Can cause serious lung inflammation; seek urgent assessment for new breathing problems.
- Can harm an unborn baby; effective contraception is needed during treatment and afterward.
- Monitor blood counts, infections, and lung symptoms during treatment.
- Capsules should be swallowed whole; do not open or crush.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for four months after the final dose.
Breastfeeding
Do not breastfeed during treatment and for four months after the final dose.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin or itraconazole, can raise midostaurin levels.
- Strong CYP3A inducers, such as rifampin or carbamazepine, can reduce its effectiveness.
- Midostaurin may affect medicines metabolized by CYP3A; review all medicines with the prescriber.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.